India revokes GSK patent on breast cancer drug Tykerb
Mumbai: India`s patent appeals board has revoked a patent granted to GlaxoSmithKline Plc`s breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.
However, the Intellectual Property Appellate Board (IPAB) upheld a patent granted to the original compound, or active pharmaceutical ingredient, citing innovative merit.
Fresenius Kabi Oncology, the Indian unit of German healthcare group Fresenius SE, had challenged patents granted for both the original molecule and it`s marketed version Tykerb, saying both molecules lacked innovation.
"We are studying the IPAB`s decision but maintain our belief in the inventiveness of the lapatinib ditosylate salt and will consider the possibility of taking further steps before the appropriate authorities to validate this," the Indian unit of UK-based GSK said in an email to Reuters on Friday.
The IPAB orders for both the patent disputes were uploaded on its website late on Thursday.
More from India
More from World
More from Sports
More from Entertaiment
- WATCH: MS Dhoni asks Jasprit Bumrah to go easy after he hurriedly ran out England skipper Eoin Morgan
- IND vs ENG, 2nd ODI: Yuvraj Singh silences critics with 14th ODI hundred, fourth against England — WATCH
- India vs England: After Virender Sehwag, Sachin Tendulkar gives Piers Morgan cricketing gyan
- WATCH: How MS Dhoni saved Yuvraj Singh's wicket with another successful DRS review
- Jallikattu protests continue in Tamil Nadu, sea of protesters camp on Marina beach